Intelligent biomarker panel development for neurometabolic disease
- PMID: 35978465
- DOI: 10.1111/dmcn.15380
Intelligent biomarker panel development for neurometabolic disease
Comment on
-
Niemann-Pick type C disease as proof-of-concept for intelligent biomarker panel selection in neurometabolic disorders.Dev Med Child Neurol. 2022 Dec;64(12):1539-1546. doi: 10.1111/dmcn.15334. Epub 2022 Jul 14. Dev Med Child Neurol. 2022. PMID: 35833379 Free PMC article.
References
REFERENCES
-
- Vanier MT. Niemann-Pick diseases. Handb Clin Neurol. 2013;113:1717-21.
-
- Vanier MT, Gissen P, Bauer P, et al. Diagnostic tests of Niemann-Pick disease type C (NP-C): A critical review. Molec Gen Metab. 2016;118:244-54.
-
- Geberhiwot T, Moro A, Dardis A, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;13:50.
-
- Papandreou A, Doykov I, Spiewak J, et al. Niemann-Pick type C disease as proof-of-concept for intelligent biomarker panel selection in neurometabolic disorders. Dev Med Child Neurol. 2022; https://onlinelibrary.wiley.com/doi/full/10.1111/dmcn.15334
-
- Mengel E, Patterson MC, Da Riol RM, et al. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results form a double-blind, randomized, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metab Dis. 2021;44:1463-80.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
